Accurate Point of Care Liver Disease Diagnostics (NCT05986916)
🩺 Plain-English Summary (8th-Grade Level)
This research study is being conducted to find out more about techniques to non-invasively evaluate liver disease. The investigators are testing a new technology to evaluate the liver (LiverScope®), and they will compare it to other methods to evaluate the liver, including advanced conventional liver MR and liver FibroScan® ultrasound exams. MR exams and FibroScan® ultrasound exams are common exams used to monitor NAFLD. Conventional MR scanners use magnetic fields and radio waves to make pictures of the liver. LiverScope® is a small, portable MR-based device that uses similar, but simplified technology, and can be used on top of an exam table in an outpatient setting. LiverScope® currently is not approved for clinical use. In this study the investigators will learn how LiverScope® measurements of the liver compare to MR. Study participants will be asked to complete a one-time visit which includes: * LiverScope exam * MR exam * FibroScan exam (optional) * Blood draw * Completion of study questionnaires
Who can join: Review the eligibility criteria below.
Location: University of California San Diego — La Jolla, California
Age range: 18 Years
🧪 Interventions in This Study
- Liverscope® exam (DIAGNOSTIC_TEST)
- MR exam (DIAGNOSTIC_TEST)
- FibroScan® exam (optional) (DIAGNOSTIC_TEST)
- Blood draw (OTHER)
- Body measurements (OTHER)
- Questionnaires (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- University of California San Diego — La Jolla, California
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in NAFLD
- Effect of VLCD on the Reduction of Liver Steatosis and Fibrosis in Subjects With Obesity and NAFLD — Iowa City, Iowa
- Nonalcoholic Fatty Liver Disease in HIV Database — Birmingham, Alabama
- LITMUS Imaging Study — San Antonio, Texas
- An Imaging-based Quantitative Biomarker Assay for NAFLD in Children — Madison, Wisconsin
- Prevalence and Predictors of Hepatic Steatosis in Persons Living With HIV — Tuscaloosa, Alabama
Explore by condition: All NAFLD clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.